About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Melanoma Clinical Trials in Pennsylvania | 457 Studies

Clinical Trials MelanomaPennsylvania

Melanoma Clinical Trials in Pennsylvania

Find 457 clinical trials for melanoma near Pennsylvania. Connect with research centers in your area.

All Melanoma trials nationwide All trials in Pennsylvania

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 181-200 of 457 trials

TerminatedA Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic MelanomaTo evaluate the antitumor activity of IPI-504 in patients with metastatic melanoma.NCT00627419·Tuscon, Arizona and 16 others CompletedA Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)The purpose of the study is to assess the efficacy, safety, and tolerability when combining pembrolizumab with epacadostat or placebo in participants with unresectable or…NCT02752074·Birmingham, Alabama and 128 others

Melanoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

CompletedSafety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted VaccineIn this study, Genocea is evaluating an investigational, personalized adjuvanted vaccine, GEN-009, that is being developed for the treatment of patients with solid tumors.NCT03633110·La Jolla, California and 10 others

WithdrawnNeoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab AloneThis study plans to test the pathologic complete response (pCR) rate of the combination biotherapy regimen consisting of nivolumab plus ipilimumab versus nivolumab alone in…NCT02736123·Pittsburgh, Pennsylvania

CompletedStudy Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant MelanomaThis is 2-part, randomized, open label, multi-center, parallel group, phase III study comparing the efficacy and safety of LGX818 plus MEK162 to vemurafenib and LGX818 monotherapy…NCT01909453·Birmingham, Alabama and 281 others

RecruitingA Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid TumorsA Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid TumorsNCT07115043·Grand Rapids, Michigan and 12 others

TerminatedStudy of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck CancerThis is a first-in-human, open-label, nonrandomized, four-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose…NCT03809624·Scottsdale, Arizona and 22 others

CompletedA Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic CancerThe purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other…NCT02857270·Washington D.C., District of Columbia and 12 others

Active not recruitingPhysician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by SurgeryThis randomized phase III trial studies how well pembrolizumab works compared with the current standard of care, physician/patient choice of either high-dose recombinant…NCT02506153·Birmingham, Alabama and 575 others

CompletedVaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic MelanomaRATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells.NCT00071981·Palo Alto, California and 64 others

Active not recruitingQUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsQUILT-3.055 is a Phase 2b, open-label, multicohort study investigating combination immunotherapies in patients with advanced solid tumors who have previously been treated with…NCT03228667·Anchorage, Alaska and 34 others

Active not recruitingA Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815This phase 1 study will investigate the safety, dosing, and initial antitumor activity of JZP815 in participants with advanced or metastatic solid tumors harboring alterations in…NCT05557045·Los Angeles, California and 14 others

CompletedA Study of PRT1419 in Patients With Advanced Solid TumorsThis is a Phase 1 dose-escalation study of PRT1419, a myeloid cell leukemia 1 (MCL1) inhibitor, in patients with advanced solid tumors.NCT04837677·Denver, Colorado and 6 others

CompletedCNS and Extracranial Tumor Tissues, CSF, and Blood From Patients With Melanoma Brain MetastasesThe purpose of this study is to collect and bank samples of blood and tissues (such as brain tissue or lymph nodes), as well as cerebrospinal fluid (CSF), which is the fluid that…NCT02058953·Pittsburgh, Pennsylvania and 2 others

Active not recruitingHigh-Dose Interferon Alfa in Treating Patients With Stage II or Stage III MelanomaRATIONALE: Interferon alfa may interfere with the growth of cancer cells.NCT00003641·Birmingham, Alabama and 532 others

CompletedVaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV MelanomaRATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells.NCT00118274·Philadelphia, Pennsylvania and 2 others

CompletedA Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic MelanomaTo evaluate the efficacy of vemurafenib in combination with cobimetinib (GDC-0973), compared with vemurafenib and placebo, in previously untreated BRAF V600 mutation-positive…NCT01689519·Birmingham, Alabama and 155 others

CompletedA Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced MalignanciesThis is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and…NCT02571036·Scottsdale, Arizona and 25 others

CompletedPhase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic MalignanciesThe purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or…NCT03126110·Los Angeles, California and 37 others

CompletedNivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic SettingThe main goal of this study is to evaluate the antitumor activity of relatlimab and nivolumab in combination in subjects with unresectable or metastatic melanoma who have not…NCT03743766·Pittsburgh, Pennsylvania

PreviousPage 10 of 23Next

Other Conditions in Pennsylvania

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Leukemia Lymphoma